Make quality healthcare reachable

Olpha, the subsidiary of JSC AB City, is one of the largest companies in the Baltic states with 50 years of experience
in the production of medicines and chemical
pharmaceutical products.

Olpha portfolio

Our product portfolio is always in continuous development

60
finished dosage forms
25
active pharmaceutical substances
20
intermediates
Olpha group

Olpha Group

Olpha Group includes a network of medical and pharmaceutical enterprises specialising in their own discipline, covering a wide range of areas.

SIA "SILVANOLS"

Developing and producing food supplements, medical devices, cosmetics and OTC medicine using natural ingredients for 28 years with the purpose of bringing the healing powers of nature to people all over the world. Silvanols.lv

SIA "TONUS ELAST"

One of the largest manufacturers of elastic medical products in Northern Europe with products ranging from bandages, compression stockings to complex back support products. Tonuselast.lv

AS "RĪGAS FARMACEITISKĀ FABRIKA"

A producer of medicinal products based on vulnerary plants and herbs with more than 70 years of experience. RFF is a Good Manufacturing Practice certified company creating products that combine nature and science. Rff.lv

SIA "JONNEX-FARMA"

Jonnex-Farma is a pharmaceutical company with expertise in developing and producing food supplements, medical devices, cosmetics, and over-the-counter (OTC) medicines using natural ingredients. Jonnex.eu

Our daily operations supported by a
professional team and a wide international coverage

Olpha Group includes a network of medical and pharmaceutical enterprises specialising in their own discipline, covering a wide range of areas.

1400+
employees
24/7
production
60
export markets

Global scope

We value local presence in our export markets to foster strong connections and seamless business.

Therefore, Olpha has representative offices in Armenia, Georgia, Mongolia, Tajikistan. Subsidiaries are located in Azerbaijan, Kazakhstan, Kyrgyzstan, Lithuania, Ukraine, Uzbekistan, as well as other countries.

Performance

120,25M €
net consolidated
turnover in 2022
100M €
investment in development
projects, 2023-2028
1+ billion
drug manufacturing capacity for
capsules and tablets per year

Company vision

Olpha aspires to improve patient lives worldwide, with the goal of ranking among the top 10 European manufacturers in our therapeutic groups.

Olpha 2030

Our current strategy plan to be achieved until 2030.

Increased focus on R&D

Adding new finished dosage forms and active pharmaceutical ingredients to our product range each year.

Development of new products

A part of our strategy is developing generics – both expanding into markets with the existing offer as well as adding new products to the portfolio.

International expansion

Our key task is expanding into new markets. The next regions are: Western Europe, the Middle East and North Africa as well as North America.

Company culture

Actively developing and maintaining our internal culture, fostering a tireless entrepreneurial spirit and “can do” attitude at all levels.

Cooperate with Olpha

Media

For media relations and partnerships

Business

For distributors and business partners

Social Cooperation

For social causes and potential projects

Careers

For open positions and career opportunties

Attention!

Information on prescription medications should only be viewed by healthcare professionals.

Are you a health care worker?